Advertisement
Advertisement

U.S. President Biden calls for intellectual property protection waivers after Omicron discovery

By:
Reuters
Updated: Nov 27, 2021, 00:41 UTC

WASHINGTON (Reuters) - U.S. President Joe Biden on Friday called on nations meeting at the World Trade Organization next week to agree to waive intellectual property protections for COVID-19 vaccines in the wake of the discovery of a new coronavirus variant in South Africa.

U.S. President Biden announces nomination of Federal Reserve Chair Powell for second four-year term at the White House in Washington

WASHINGTON (Reuters) -U.S. President Joe Biden on Friday called on nations expected to meet at the World Trade Organization next week to agree to waive intellectual property protections for COVID-19 vaccines in the wake of the identification of a new coronavirus variant in South Africa.

However, the meeting he was referring to was later postponed after the new variant led to travel restrictions that would have prevented many participants from reaching Geneva.

“The news about this new variant should make clearer than ever why this pandemic will not end until we have global vaccinations,” Biden said in a statement.

“This news today reiterates the importance of moving on this (waiving intellectual property protections) quickly.”

The Biden administration faces fresh criticism over a failure to get vaccines to poorer countries while supplying free booster shots to Americans, after the new variant named Omicron was identified.

(Reporting by Nandita Bose, writing by Lucia Mutikani and Heather Timmons, editing by Chris Reese)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement